Taipei, Taiwan, August 9, 2024 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company based in Taiwan, has reported its unaudited consolidated revenue for July 2024 at NT$2,722 million, amounting to NT$2,722 million. This positions July as the peak revenue-generating month of the year so far and the second-highest monthly revenue in the company's history.
This exceptional performance is largely attributed to the significant shipments of Lenalidomide to the US market, driving a substantial 144% month-over-month and 19% year-over-year growth.
The company's export revenue saw a remarkable 471% month-over-month and 53% year-over-year increase, fueled by the strong demand for Lenalidomide. Meanwhile, revenue from Asia declined 25% year-over-year, primarily due to the absence of a one-time NT$186 million royalty in Korea, which was recognized in the same period last year.
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S., Europe, Japan, China, and Brazil. Lotus runs over 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over 250 commercial products. The Company invests in diversified best portfolio consisting of high-barrier oncology, complex generics as well as 505(b)2 and NCE via internal R&D investment and licensing-in partnership, and also strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.
Media Inquiries:
Yu-ying Yang, Associate Director, Corporate communication.
+886 2 2700 5908
investor@lotuspharm.com